Docimo Raffaella, Montesani Luigi, Maturo Paulo, Costacurta Micaela, Bartolino Michela, DeVizio William, Zhang Yun Po, Cummins Diane, Dibart Serge, Mateo Luis R
University of Rome at Tor Vergata, Department of Odonto Stomatology (Cattedra Di Pedodonzia), Rome, Italy.
J Clin Dent. 2009;20(1):17-22.
This paper presents the results of one of two eight-week dentin hypersensitivity clinical studies in which the efficacy of a novel toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP) was compared to that of a benchmark commercial toothpaste containing 2% potassium ion, dosed as 3.75% potassium chloride, and 1450 ppm fluoride as sodium fluoride (NaF).
An eight-week clinical study, with eighty patients, was conducted in Rome, Italy using a double-blind, stratified, two-treatment design. Tactile sensitivity assessments, as well as air blast sensitivity assessments, were used to compare the efficacy of the two products.
This clinical study showed that the new toothpaste containing 8.0% arginine and 1450 ppm fluoride as MFP in a calcium carbonate base provided a significant reduction in dentin hypersensitivity when used over a period of eight weeks. The study also showed that this new arginine toothpaste provided significantly greater reductions (p < 0.05) in dentin hypersensitivity in response to tactile (37.0%, 30.0%, and 12.2%) and air blast (23.9%, 32.0%, and 29.3%) stimuli than the commercial sensitive toothpaste containing 2% potassium ion and 1450 ppm fluoride as NaF in a silica base, after two weeks, four weeks, and eight weeks of product use, respectively.
A new toothpaste containing 8.0% arginine calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP) provides significantly increased dentin hypersensitivity relief (p < 0.05) compared to a commercial sensitive toothpaste containing 2% potassium ion after two weeks, four weeks, and eight weeks of product use.
本文介绍了两项为期八周的牙本质过敏临床研究之一的结果,该研究将一种含有8.0%精氨酸、碳酸钙和1450 ppm氟(以单氟磷酸钠,即MFP形式存在)的新型牙膏与一种基准市售牙膏进行了疗效比较,后者含有2%钾离子(以3.75%氯化钾形式给药)和1450 ppm氟(以氟化钠,即NaF形式存在)。
在意大利罗马进行了一项为期八周的临床研究,有80名患者参与,采用双盲、分层、双治疗设计。通过触觉敏感性评估以及气喷敏感性评估来比较两种产品的疗效。
这项临床研究表明,在碳酸钙基质中含有8.0%精氨酸和1450 ppm氟(以MFP形式存在)的新型牙膏,在使用八周的时间里能显著降低牙本质过敏。该研究还表明,在分别使用产品两周、四周和八周后,这种新型精氨酸牙膏在应对触觉(降低37.0%、30.0%和12.2%)和气喷(降低23.9%、32.0%和29.3%)刺激时,相比在二氧化硅基质中含有2%钾离子和1450 ppm氟(以NaF形式存在)的市售敏感牙膏,能更显著地降低牙本质过敏(p < 0.05)。
在分别使用产品两周、四周和八周后,与含有2%钾离子的市售敏感牙膏相比,一种含有8.0%精氨酸、碳酸钙和1450 ppm氟(以单氟磷酸钠,即MFP形式存在)的新型牙膏能显著增强缓解牙本质过敏的效果(p < 0.05)。